CYP19A1 and polycystic ovary syndrome: As a nonsteroidal aromatase inhibitor, letrozole restrains the conversion of androgen to estrogen, leading to androgen accumulation and ultimately recapitulating both reproductive and metabolic PCOS phenotypes in rats and mice [41, 42].